New AI-powered research suggests that GLP-1 drugs, commonly used for diabetes and obesity, could prevent up to 34,000 heart attacks and strokes annually by offering cardiovascular benefits to millions of Americans.

Roche announces positive Phase I trial results for CT-996, a new oral GLP-1 receptor agonist for type 2 diabetes and obesity. The study shows significant weight loss and good tolerability, paving the way for further development.

Explore Noom Vibe, Noom's latest app tailored for the GLP-1 era. Track healthy habits, earn rewards, and connect with a supportive community for a comprehensive approach to wellness.

Explore the Obesity Bill of Rights: An initiative aimed at enhancing access to quality obesity care for Americans. Learn more about this significant healthcare development.

The Ontario government is making big changes in how people can get Ozempic, a medicine mainly used for Type 2 diabetes. This shift is happening because more and more people want Ozempic, especially after celebrities like Oprah Winfrey praised it as a fantastic weight loss solution. This huge demand for Ozempic has caused a shortage in supply. Sadly, it means that people with Type 2 diabetes are finding it harder to get this medicine through the Ontario Drug Benefit (ODB) program.

Learn about the rising cases of semaglutide overdose reported by American Poison Centers and the growing use of weight loss medications like Ozempic® and Wegovy®. Understand the risks associated with these drugs, initially developed for type 2 diabetes but now popular for weight loss.